Skip to main content
. 2021 Dec 2;12:792691. doi: 10.3389/fimmu.2021.792691

Table 3.

FDA approved main agents of immune checkpoint inhibitors (ICIs) for colorectal cancer (CRC).

Regimen Target population FDA approved date Registration number Reference
PD-1 inhibitor
Pembrolizumab Unresectable or metastatic dMMR and high microsatellite instability (MSI-H) CRC 23 May 2017 NCT01876511
KEYNOTE-164
KEYNOTE-177 (NCT02563002)
(243245)
Nivolumab DMMR and MSI-H mCRC 1 August 2017 CheckMate 037
CheckMate 066
CheckMate 142 (NCT02060188)
(246248)
PD-1 + CTLA-4 inhibitor
Nivolumab + Ipilimumab DMMR and MSI-H mCRC 10 July 2018 CheckMate 142 (249251)